BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23153538)

  • 1. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.
    Bicocca VT; Chang BH; Masouleh BK; Muschen M; Loriaux MM; Druker BJ; Tyner JW
    Cancer Cell; 2012 Nov; 22(5):656-67. PubMed ID: 23153538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia.
    Fei F; Stoddart S; Müschen M; Kim YM; Groffen J; Heisterkamp N
    Leukemia; 2010 Apr; 24(4):813-20. PubMed ID: 20111071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
    Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
    Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.
    Broome HE; Rassenti LZ; Wang HY; Meyer LM; Kipps TJ
    Leuk Res; 2011 Oct; 35(10):1390-4. PubMed ID: 21813176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
    Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CBP Modulates Sensitivity to Dasatinib in Pre-BCR
    Duque-Afonso J; Lin CH; Han K; Morgens DW; Jeng EE; Weng Z; Jeong J; Wong SHK; Zhu L; Wei MC; Chae HD; Schrappe M; Cario G; Duyster J; Xiao X; Sakamoto KM; Bassik MC; Cleary ML
    Cancer Res; 2018 Nov; 78(22):6497-6508. PubMed ID: 30262461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL.
    Chow M; Gao L; MacManiman JD; Bicocca VT; Chang BH; Alumkal JJ; Tyner JW
    Oncogene; 2018 Sep; 37(38):5221-5232. PubMed ID: 29849118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of receptor tyrosine kinase-like orphan receptor 1 in preeclampsia placenta inhibits human trophoblast cell proliferation, migration, and invasion by PI3K/AKT/mTOR pathway accommodation.
    Chen J; Yue C; Xu J; Zhan Y; Zhao H; Li Y; Ye Y
    Placenta; 2019 Jul; 82():17-24. PubMed ID: 31174622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
    Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
    PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).
    Krause S; Pfeiffer C; Strube S; Alsadeq A; Fedders H; Vokuhl C; Loges S; Waizenegger J; Ben-Batalla I; Cario G; Möricke A; Stanulla M; Schrappe M; Schewe DM
    Blood; 2015 Jan; 125(5):820-30. PubMed ID: 25428221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
    Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
    Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
    Ida L; Yamaguchi T; Yanagisawa K; Kajino T; Shimada Y; Suzuki M; Takahashi T
    Cancer Sci; 2016 Feb; 107(2):155-61. PubMed ID: 26661061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
    Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
    J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
    Glover JM; Loriaux M; Tyner JW; Druker BJ; Chang BH
    Pediatr Blood Cancer; 2012 Sep; 59(3):576-9. PubMed ID: 22038978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.
    Müschen M
    Blood; 2015 Jun; 125(24):3688-93. PubMed ID: 25878119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K/Akt/mTOR signaling pathway.
    Mao Y; Xu L; Wang J; Zhang L; Hou N; Xu J; Wang L; Yang S; Chen Y; Xiong L; Zhu J; Fan W; Xu J
    Biofactors; 2019 May; 45(3):416-426. PubMed ID: 30801854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.